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Abstract The objective ofthis studywas to compare the in£ammatorymarkereosinophilcationic protein (ECP) with
peakexpiratory £ow (PEF) in determining the therapeutic needs of inhaled corticosteroids in asthma patients assessed
as asthma symptoms.Arandomized, single-blind studyover 6 monthswasperformed at six specialistcentres in Europe.
In total,164 adult patientswithmoderate to severe symptomatic asthma andregular use of inhaled corticosteroidswere
included.After a run-inperiodof 2weekspatientswererandomlyallocatedtothe ECPor the PEFmonitoring group.The
dose of inhaledcorticosteroidswas adjustedevery fourthweekbasedonthe current serum ECPvalue orpre-broncho-
dilatormorning PEF values as surrogatemarkers oftherapeutic needs.Atthe endofthe study therewereno statistically
signi¢cant di¡erences in the mean daily symptom score or the percentage of symptom-free days between the two
groups.The mean daily dose of inhaled corticosteroids was similar in the two groups at the start of the study but the
algorithms used to adjust the dose of inhaled corticosteroids resulted in an increased use of inhaled corticosteroids in
both groups.Themean daily dose of inhaled corticosteroids over thewhole study periodwas signi¢cantly lower in the
ECPgroup comparedwiththe PEF group (1246 vs.1667 mg, P=0?026).Inthe ECPgroup, forced expiratory volumein1sec
(FEV1)% predictedwaslowerattheendofthe studycomparedwiththebegining (92% vs.87%,P=0?0009), althoughthere
wasno signi¢cantdi¡erencebetweenthetwogroups.None oftheused algorithms for ECPand PEFledto improvement
in symptom scores, in spite of increased doses of inhaled corticosteroids.In this respect, bothmethodswere equivalent
and insu⁄cient.Recommendations suggesting lung function tests in current guidelines may be di⁄cult to translate into
clinicalpractice, however, a combinationof in£ammatorymarkers, lung functionandsymptomsmaystillimprove asthma
control.r2001Elsevier Science Ltd
doi:10.1053/rmed.2001.1218, available online athttp://www.idealibrary.comon
Keywords asthma; corticosteroids; eosinophil cationic protein; in£ammation; PEF.INTRODUCTION
Asthma has been demonstrated to be greatly dependent
on in£ammatory processes including activated eosino-
phils (1,2).Various guidelines for asthma management (3,
4) propose thatmeasurements of lung function and spe-
ci¢cally peak expiratory £ow (PEF) are most helpful inReceived 27 March 2001, accepted in revised form11September 2001
and published online12 December 2001.
Correspondence should be addressed to: Prof.Olle L˛whagen,
Sahlgrenska University Hospital, SE-413 45 Gothenburg, Sweden.Fax:
+46-31-417824; E-mail: olle.lowhagen@lungall.gu.seindicating the therapeutic need in moderate to severe
asthma.However, lung function variables and PEF relate
only indirectly to theunderlying in£ammatoryprocess in
the airways and also re£ect the bronchoconstriction re-
lated to irritation andhyper-responsiveness (5,6).Thus, it
can be argued that, since asthma is an in£ammatory dis-
ease, theremay be a bene¢t if the in£ammatory process
could be re£ectedmore directly over time (7).
In active asthma, there is evidence of recruitment of
primed eosinophils from the bone marrow into the air-
ways (8). Eosinophil cationic protein (ECP), a cytotoxic
granule-derived protein released from activated
FIG. 1. Schedule for dosing inhaled corticosteroids. (a) At 2
consecutive visits, (b) during prior 2 months and (c) during last
weekbefore visit.The dose stepsrepresent budesonide.For be-
cloomethasone dipropionate, corresponding doses were 0^
250^500^1000^2000^3000^4000 mgdayÿ1. In case of exacer-
bation, the inhaled steroid dose was increased one step after a
course of oral steroids.
96 RESPIRATORYMEDICINEeosinophils, has been found released in the airways of
asthmatic patients responsive to corticosteroid therapy
(9,10). Serum ECP is assessed as the ex vivo release from
primed eosinophil granulocytes incubated at room tem-
perature (11).
Studieshave demonstrated ECPrelease into theblood
from activated eosinophils during the late asthmatic re-
action (12). Serum ECP levels have been shown to re£ect
exposure to allergens, deterioration of asthma (9,13), dis-
ease activity (14) and response to corticosteroid treat-
ment (15^18).
The aim of thepresent study was to compare the clin-
ical outcome when serum ECP, a marker of in£amma-
tion, or PEF, a measure of bronchial obstruction, were
used to guide the dose of inhaled corticosteroids re-
quired to control asthma.
METHODS
Study subjects
One hundred and sixty-four patients with moderate to
severe asthma, step 3^4 according to the asthma guide-
line (3), 16^65 years old with documented symptoms
during the last 12 months, 15% reversibility in PEF or
forced expiratory volume in 1sec (FEV1) after use of a
bronchodilator or in response to a trial of corticosteroid
therapy, and regular use of inhaled corticosteroids (400^
1600mgdayÿ1 budesonide or 500^2000mgdayÿ1 beclo-
methasone dipropionate but not £uticasone) were en-
rolled in a 6-month study. Exclusion criteria were use of
oral corticosteroids, anti-histamines, smokingduring the
last 24months and/or smoking 5 pack-years during the
last10 years, and any known co-morbidity.
Study design andmethods
The study was a parallel group, randomized single-blind
study, involving six centres in Gothenburg (Sweden),The
Hague (The Netherlands), Antwerp (Belgium) and Veru-
no, Pavia and Crema (Italy).
At the ¢rst visit case history, use of asthma medica-
tion, physical examination, spirometry, eosinophil count,
serum ECP and speci¢c IgE (Phadiatops) were assessed.
Each patient was given a diary card for daily recording of
cough, wheeze or breathlessness during daytime, night-
time and after exercise on an 0^3 scale (maximum total
score 21) and to record morning PEF and medication
usage during a run-in period of 2 weeks. The personal
best post-bronchodilator morning PEF (mini-Wright
Peak FlowMeter,ClementClarke International Ltd,Har-
low,U.K. ) was established during this period.Treatment
allocation to the ECP or PEF groupwas performed after
run-in using a computer-generated randomization sche-
dule prepared for each centre.After the run-in period, the patients visited the clinic
every fourth week 77 days for clinical assessment. At
each visit, the diary card was checked and FEV1, eosino-
phil count, serum ECP and pre-bronchodilation PEF
weremeasured at the same time of the day and regard-
less of group allocation. Patients were instructed not to
use short- and long-acting b2-adrenoceptor agonists 4
and 12h respectively prior to the FEV1 measurement.
All asthma medications were kept constant during the
study period except the as required use of short-acting
b2-adrenoceptor agonists and inhaled corticosteroids.
The algorithms used in the present study were based on
international consensus (3,4) and clinical data from stu-
dies in various countries (12^17).The schedule for dosing
inhaled corticosteroids is shown in Fig.1.The dose steps
represent budesonide. For beclomethasone dipropio-
nate, the dose steps were 0^250^500^1000^2000^
3000^4000mgdayÿ1.
Serum ECP (19) was measured with UniCAPs (Phar-
macia Diagnostics,Uppsala, Sweden) according to the di-
rections for use.Depending on the PEF values during the
preceding period (PEF group) or the current ECP value
(ECP group), the patient was instructed within 72h of
each visit to adjust the dose of inhaled corticosteroids
based on the algorithm as depicted in Fig.1.
The primary clinical end pointwas asthma symptoms,
expressed both as symptom score and symptom-free
days. Secondaryendpointswereuse of inhaled short-act-
ing b2-adrenoceptor agonists, FEV1 and asthma exacer-
bations. The criteria for an exacerbation were one or
several of the following: morning pre-bronchodilator
PEFo60% of personal best for  2 days during the last
7 days; nocturnal awakening needing a bronchodilator
more than once during 1 night or more than 3 nights in
the previous 7 nights; increase of 4 points in symptom
TABLE 1. Dispositionofpatients, shownfor thewhole study





Randomized 164 85 79
Completed 135 74 61
Completed and compliantwith





Withdrawnduring follow-up 24 8 16
Withdrawnwithnovalid data 5 3 2
ECPCOMPAREDWITHPEF TODECIDECORTICOSTEROIDDOSE 97score for  2 consecutive days: increase in daily use of
short-acting inhaled b2-adrenoceptor agonists of  4
doses for 2 days.Patientswho exacerbatedwere given
oral prednisone 30mg daily for 5^7 days and were kept
in the trial on a one step higher dose of inhaled corticos-
teroids, whichwas not changed at the next visit.
The study was conducted in accordancewith theprin-
ciples of The Declaration of Helsinki and Good Clinical
Practice. Approval from the Ethics Committee at each
centrewas obtained.
Statistical analyses
The sample size was calculated from an expected risk of
having a certain value or higher on the symptom score
when ECP was used compared to PEF (odds ratio of
0?4^0?5). The study then required 58^98 patients in
each group to have an 80% power of detecting a di¡er-
ence at a two-sided 5% signi¢cance level (20). Allpatients
who completed the study, adhered to the protocol con-
ditions andwhohadnotviolated amajor eligibility criter-
ion were included in the ‘per protocol’ (PP) analysis. All
statistical tests were two-sided with a signi¢cance level
of 5%.The analyses were based on results from the last
seven days preceding each visit. Analysis of variance and
analysis of covariance were used for the variable intake
of inhaled corticosteroids and FEV1. Logistic regression
(proportional hazardsmodel) was used for the variables
symptom score and intake of inhaled short-acting b2-
adrenoceptor agonists. The models included the e¡ects
of country, treatment group and values at run-in. Treat-
ment group-by-country interaction terms for the out-
come variables were included if the associated
statistical test yielded a two-sided P-value of 0?10 or less.
Student’s t-test (paired) was used to test the within-
group changes of FEVl and inhaled corticosteroids be-
tween visit 2 and visit 8.
Wilcoxon signed ranks test was used for symptom
score variables and intake of short-acting b2-adrenocep-
tor agonists. Mantel^Haenszel statistic adjusting for
country was used for comparison between groups for
theproportion of patientswith at leastone exacerbation
during the study period as well as the proportion of pa-
tients using long-acting b2-adrenoceptor agonists.
RESULTS
Of the 164 patients enrolled, 24 did not complete the
study (12 for medical reasons and 12 for social reasons)
(Table1), and ¢ve left the study after the ¢rst or second
visit, with no valid data. In total, 135 patients completed
the 6-month study. Out of these 135, 118 adhered to all
study conditions and were included in the per protocol
analysis. Of the randomized patients who were not in-
cluded in the PP analysis,17 completed the study but de-viated from the intended medication schedule. On the
basis of history of allergy and Phadiatop test (screening
test for presence of speci¢c IgE), the patients were di-
vided into allergic (n=41), non-allergic (n=46) and
mixed asthma (n=31) (Table 2).No di¡erence in baseline
characteristics between the two groups was found (Ta-
ble 2).The concomitantmedication is shown inTable 3.
Symptoms
The mean daily symptom score was1?8 at visit 2 and 2?1
at visit 8 in the ECP group, and 1?4 and 1?7 in the PEF
group (Table 4).Within-group di¡erences between visits
2 and 8 were not signi¢cant, and therewas no di¡erence
between the groups during the study period.The mean
percentage of symptom-free days was 40% at visit 2 and
45% atvisit 8 in the ECPgroup, and 56 and 50% in the PEF
group. Within-group di¡erences were not signi¢cant,
and there was no di¡erence between the groups at the
end of the study. There were no signi¢cant di¡erences
between patients with allergic and non-allergic asthma
in any of the groups.
Short-acting b2-adrenoceptor agonists
The mean percentage of days without intake of short-
acting b2-adrenoceptor agonists at visits 2 and 8 was 73
and 64% in the ECP group, and 76 and 74% in the PEF
group, respectively (Table 4).The mean daily intake was
not signi¢cantly changed in either of the groups and no
di¡erence between the groups was found.
Spirometry
Mean FEV1% predicted in the ECP group at visit 2 and
visit 8 were 92 and 87 (P=0?0009), respectively and in
the PEF group 90 and 89 (NS).No signi¢cant di¡erences
were found between the groups, either at the beginning
or at the end of the study (Table 4).
TABLE 2. Clinical baseline characteristics.Mean and 95% con¢dence intervals






Height (m) 1?69 1?69 P =0?93
(1?67^1?72) (1?67^1?72)
Weight (kg) 75?9 72?0 P =0?13
(72?0^79?8) (68?6^75?3)
Sex (F/M) 36/29 26/27 P=0?48
PEF (% predicted)* 103?4 103?6 P=0?92
(97?9^108?8) (99?1^108?0)
ECP (mglÿ1) 12?0 11?6 P=0?87
(10?0^14?4) (9?6^14?2)
Eosinophils (109lÿ1) 0?20 0?22 P =0?53
(0?17^0?24) (0?17^0?27)
Phadiatop (negative/positive) 24/41 16/37 P=0?45
Type of asthma (allergic/mixed/non-allergic) 23/16/26 18/15/20 P=0?90
Duration of asthma (o2 yrs/2^10 yrs/410 yrs) 5/31/29 3/21/29 P=0?29
*Thehighestof threemeasurements.
TABLE 3. Concomitantmedication













During the study 14 patients in the ECP group experi-
enced 18 exacerbations and seven patients in the PEF
group experienced eight exacerbations. The di¡erence
between the groups did not reach statistical signi¢cance
(Table 4).
Use of corticosteroids
Based on the treatment algorithm there was a need to
change therapy in all patients but one.During the run-in
period the mean daily dose of inhaled corticosteroids
was 928mg in the ECPgroup and 943mg in the PEF group
(NS,Table 4,Fig. 2). In the ECPgroup andin the PEF group
themean daily dose increased during the study period to
1272mg (P=0?03) and 1540mg (P=0.0004), respectively.
Calculated over the whole study period the mean daily
dose was signi¢cantly higher in the PEF group (1667mg)
comparedwith the ECP group (1246mg,P=0?026).ECP and eosinophil counts
For all patients, the correlation coe⁄cient between
ECP and the number of eosinophils at the di¡erent
visits varied between 0?37 and 0?54. An overall estimate
of the correlation coe⁄cient for all eight visits obtained
by analysis of covariance was 0?46. Fifty-¢ve per cent of
the patients with serum ECP between 20 and 40mglÿ1
had an eosinophil count above the upper reference limit.
In patients with ECP  40mg lÿ1, 40% were above this
limit.
DISCUSSION
A number of studies have suggested that serum ECP
levels may be useful in guiding the dose of inhaled corti-
costeroids to control asthma (15^18). In the present
study an attempt was made to compare this method
with a traditionalmethod, using PEF.
The advantages of serum ECP measurement are its
objectivity and accuracy. The disadvantages today may
be practical problems of blood handling and some delay
in results (19).The advantages of PEF are self-use and sim-
plicity. The disadvantages are the need for compliance
and the di⁄culty for some patients, especially small chil-
dren, to accomplish themeasurements properly (5,6).
The clinical decision on how to dose inhaled cortico-
steroids optimally to maintain asthma control is not
always easy. For the individual patient, information in-
cluding history of symptoms, limitations to daily living,
clinical ¢ndings and lung function shouldbe evaluated to-
gether by the treating physician to best ¢nd the optimal
dose. It is well known that this optimal situation is not
always achieved and suboptimal treatment of asthma is
TABLE 4. Clinical data.Mean and 95% con¢dence intervals
Variable Period ECPgroup PEF group P-value*
Daily symptom score Run-in 1?8 (1?3^2?3) 1?4 (0?9^2?0) 0?11w
End of study 2?1 (1?4^2?8) 1?7 (1?0^2?3) 0?76
Percentage of Run-in 40 (31^50) 56 (45^68) 0?07z
symptom-free days End of study 45 (34^57) 50 (38^62) 0?91
Daily intake of
short-acting b2- Run-in 0?18 (0?09^0?28) 0?13 (0?05^0?21) 0?39
w
adrenoceptor agonists (mgdayÿ1) End of study 0?26 (0?14^0?38) 0?17 (0?08^0?26) 0?75
Percentage of days Run-in 73 (63^82) 76 (66^86) 0?34w
withno intake of
short-acting b2-adrenoceptor agonists
End of study 64 (53^74) 74 (64^84) 0?41
FEV1inpercentof predicted Run-in 92?1 (87?2^97?0) 89?8 (85?0^94?6) 0?51
z
End of study 87?1 (82?6^91?6) 89?1 (84?5^93?6) 0?09
Numberof exacerbatingpatients, n (%) Whole studyperiod 14 (22) 7 (13) 0?20}
Daily intake of inhaled corticosteroids (mg) Run-in 928 (828^1028) 943 (833^1054) 0?88z
End of study 1272 (975^1568) 1540 (1198^1881) 0?25
*Two-sided P values for the comparison between ECPgroup and PEF group. P-values at run-in are adjusted for variation due to
country.P-values atthe end ofthe study are adjusted for values at run-in andvariation due to country.
wP-values fromlogistic regression (proportionalhazardsmodel).
zRun-in: P-value fromanalysis of variance.End of study: P-value fromanalysis of covariance.
}P-value fromMantel^Haenszel statistic adjusting for country.
FIG. 2. Mean daily intake of inhaled corticosteroids for the 7 days preceding each visit to the clinic.ECPgroup ( )^, n=65;PEF group
(- - -), n=53.Verticalbars show the 95% con¢denceintervals.P-valuesrefer towithin-groupchangesbetweenstartandendofthe study.
The inserted table shows themeandailydose of inhaled corticosteroids during thewhole studyperiod.
ECP COMPAREDWITHPEF TODECIDECORTICOSTEROIDDOSE 99common (21^23). To support treating physicians in their
therapeutic decisions, guidelines for asthma manage-
ment have been developed (3,4) but it is not obvious
how the recommendations should be translated into
clinical practice.The steps of doing the treatment are gi-
ven, but atwhat indications should one go fromone dose
level to another?
Based on the currently available guidelines and clinical
experience an attempt was made in this study to con-
struct two algorithms for guiding the inhaled steroiddose, one for ECP as a marker of in£ammation, and one
for PEF as a lung function test. However, it was shown
that there was no di¡erence in symptoms between the
two modalities of guiding the dose and, in fact, the pri-
mary clinical end points, symptom score and symptom-
free days, were not improved. The algorithm for ECP led
to a signi¢cant fall in FEV1despite increase in steroiddose
andwithout change in symptoms.The algorithm for PEF,
suggested in published guidelines (3,4), led to a signi¢-
cantly higher dose of inhaled steroids without gain in
100 RESPIRATORYMEDICINEsymptoms but with a potential risk of more side-e¡ects.
Thus, both ways of guiding the steroid dose seem to be
insu⁄cient.
It is now known that the dose response curve to in-
haled steroids (especially athighdoses) is £at, and amean
change in daily dose from 900 to1200 or 1500mg, rarely
results in much change in lung function or symptoms. In
one study, even a four-fold di¡erence (200 vs. 800mg) for
oneyear, in patients of severity similar to that in the pre-
sent study, did notresult in signi¢cantdi¡erences regard-
ing symptoms or lung function (24).These results were,
however, not known when the current study was
planned. In a recent study it was suggested that percen-
tage sputum eosinophils, another marker of in£amma-
tion, might be useful in guiding the reduction of inhaled
steroid doses in asthma (25). As in almost every trial it is
not fully known to what extent the patients complied
with the given instructions regarding treatment.The re-
ported treatment in diarieswas however close to the in-
tended ones, and, in our opinion, there is no reason to
believe that poor compliance a¡ected the results consid-
erably.
The study showed that neither ECP nor PEF might be
an idealway for guiding the optimal dose of inhaled ster-
oids. In spite of this, the results are of interest. Firstly, it
seems that guidelines have limitations when transferred
to clinical practice.Does PEF values below 85% of perso-
nal best signal poor asthma control, and is it really cor-
rect to increase steroid dose due to reduced PEF? ECP
seems to be comparable to PEF in this respect. Secondly,
the study seems to support the clinical experience that
asthma is a heterogeneous disease. This is indicated by
the lack of strong correlation between di¡erent para-
meters of asthma. Increased doses of inhaled steroids,
generally considered as potent drugs in asthma, were
not followed by an improvement of symptoms. FEV1was
decreased in the ECP group despite higher doses of ste-
roids, and airway in£ammation, expressed as serum-
ECP, seems not to have a direct relationshipwith asthma
symptoms.Furthermore, asthma symptomsmay also be
heterogeneous and all symptoms commonly used in
asthma studies, may not re£ect reversible bronchial ob-
struction, e.g. coughmaynotbe induced in the sameway
as wheezing and breathlessness may not be an ‘asthma-
speci¢c’ symptom (26). Asthma-like disorders, such as
sensory hyper-reactivity (27), have also been described
where asthma-like symptoms are present but not asso-
ciatedwith reversible bronchial obstruction and positive
methacholine test (26,27). Although airway symptoms
andquality of life are recommended as clinical endpoints,
itmay be important to further analysewhich symptoms
are themost ‘asthma-speci¢c’.
From a clinical standpoint the conclusion of this con-
trolled study of a marker of in£ammation, may be that
neither the algorithm for ECP nor PEF lead to improve-
mentof asthma symptoms.However, a reservationmustbe done for di¡erent e¡ects in certain subtypes of asth-
ma and for di¡erent airway symptoms. This needs
further studies. We also think that a combination of a
lung function test and ECP, together with the history of
symptoms and physical status, still may be a good way of
guiding the steroid dose.
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